Log in

Relevant bibliographies by topics / (H1N1) 2009 Monovalent Vaccine / Journal articles

To see the other types of publications on this topic, follow the link: (H1N1) 2009 Monovalent Vaccine.

Journal articles on the topic '(H1N1) 2009 Monovalent Vaccine'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '(H1N1) 2009 Monovalent Vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

N, K. Mishra* J. R. Panda Santanu Kumar Hotta. "SWINE FLU (2009 H1N1 INFLUENZA) AND IT'S MONOVALENT VACCINATION." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4451–54. https://doi.org/10.5281/zenodo.1066275.

Full text

Abstract:

Swine flu (2009 H1N1) is a mutational modified strain of the influenza virus. Many countries have been affected with this virus globally and it has been declared a pandemic influenza strain. 2009 H1N1 virus is a communicable disease which spreads from person to person through coughing, sneezing, nasal secretion and handling of objects which is contaminated with the virus. It is an ideal way to prevent swine flu by taking of early vaccination. Influenza A (H1N1) 2009 Monovalent vaccine is an inactivated influenza virus indicated for active immunization of persons age 6months and older against i

APA, Harvard, Vancouver, ISO, and other styles

2

Song, Joon Young, Hee Jin Cheong, Yu Bin Seo, et al. "Comparison of the Long-Term Immunogenicity of Two Pandemic Influenza A/H1N1 2009 Vaccines, the MF59-Adjuvanted and Unadjuvanted Vaccines, in Adults." Clinical and Vaccine Immunology 19, no. 5 (2012): 638–41. http://dx.doi.org/10.1128/cvi.00026-12.

Full text

Abstract:

ABSTRACTSince the first reports of the A/H1N1 virus in April 2009, the pandemic influenza virus spread globally and circulated for a long time. The primary method for the control of influenza is vaccination, but levels of influenza vaccine-induced antibody are known to decline rapidly during a 6-month period. In adults aged 18 to 64 years, we compared the long-term immunogenicity of two of the influenza A/H1N1 2009 monovalent vaccines, 3.75-μg MF59-adjuvanted vaccine and 15-μg unadjuvanted vaccine. The serum hemagglutinin inhibition (HI) titers were determined prevaccination and at 1, 6, and 1

APA, Harvard, Vancouver, ISO, and other styles

3

Song, Joon Young, Hee Jin Cheong, Yu Bin Seo, et al. "Long-Term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine among Health Care Workers: Influence of Prior Seasonal Influenza Vaccination." Clinical and Vaccine Immunology 20, no. 4 (2013): 513–16. http://dx.doi.org/10.1128/cvi.00725-12.

Full text

Abstract:

ABSTRACTHealth care workers (HCWs) are at great risk of influenza infection and transmission. Vaccination for seasonal influenza is routinely recommended, but this strategy should be reconsidered in a pandemic situation. Between October 2009 and September 2010, a multicenter study was conducted to assess the long-term immunogenicity of the A/H1N1 2009 monovalent influenza vaccine among HCWs compared to non-health care workers (NHCWs). The influence of prior seasonal influenza vaccination was also assessed with respect to the immunogenicity of pandemic H1N1 influenza vaccine. Serum hemagglutini

APA, Harvard, Vancouver, ISO, and other styles

4

Greenberg, Michael E., Michael H. Lai, Gunter F. Hartel, et al. "Response to a Monovalent 2009 Influenza A (H1N1) Vaccine." New England Journal of Medicine 361, no. 25 (2009): 2405–13. http://dx.doi.org/10.1056/nejmoa0907413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Arya, Subhash C., and Agarwal Nirmala. "Influenza A (H1N1) 2009 monovalent vaccine: Laboratory confirmation of vaccine breakdowns." Vaccine 27, no. 49 (2009): 6808. http://dx.doi.org/10.1016/j.vaccine.2009.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Clark, Tristan W., Manish Pareek, Katja Hoschler, et al. "Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine." New England Journal of Medicine 361, no. 25 (2009): 2424–35. http://dx.doi.org/10.1056/nejmoa0907650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schauer, Stephanie L., Daniel J. Hopfensperger, Matthew J. Verdon, Thomas R. Maerz, Gerald W. Gabor, and Jeffrey P. Davis. "An Immunization Information System to Meet Evolving Needs During the 2009-2010 Influenza A (H1N1) Vaccination Campaign." Disaster Medicine and Public Health Preparedness 6, no. 4 (2012): 402–7. http://dx.doi.org/10.1001/dmp.2012.64.

Full text

Abstract:

ABSTRACTIn 2009, a monovalent H1N1 influenza (H1N1) vaccine was manufactured in response to the pandemic of 2009 influenza A (H1N1) virus infection that emerged earlier in the year. The overall allocation of the H1N1 vaccine to the states was the purview of the federal government; thereafter, the states were accountable for distributing and reporting the number of doses of H1N1 vaccine administered weekly. This report describes how the Wisconsin Immunization Registry (WIR) was updated and used during the H1N1 immunization campaign and its role in meeting the federal H1N1 immunization reporting

APA, Harvard, Vancouver, ISO, and other styles

8

O'Donnell, Christopher D., Amber Wright, Leatrice Vogel, Kobporn Boonnak, John J. Treanor, and Kanta Subbarao. "Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus." Clinical and Vaccine Immunology 21, no. 5 (2014): 737–46. http://dx.doi.org/10.1128/cvi.00790-13.

Full text

Abstract:

ABSTRACTThe hypothesis of original antigenic sin (OAS) states that the imprint established by an individual's first influenza virus infection governs the antibody response thereafter. Subsequent influenza virus infection results in an antibody response against the original infecting virus and an impaired immune response against the newer influenza virus. The purpose of our study was to seek evidence of OAS after infection or vaccination with the 2009 pandemic H1N1 (2009 pH1N1) virus in ferrets and humans previously infected with H1N1 viruses with various antigenic distances from the 2009 pH1N1

APA, Harvard, Vancouver, ISO, and other styles

9

ENGLUND, H., H. CAMPE, and W. HAUTMANN. "Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season." Epidemiology and Infection 141, no. 9 (2012): 1807–15. http://dx.doi.org/10.1017/s0950268812002282.

Full text

Abstract:

SUMMARYWe estimated the vaccine effectiveness (VE) of trivalent and monovalent influenza vaccines, respectively, against laboratory-confirmed influenza infections in patients with influenza-like illness who visited physicians participating in the Bayern Influenza Sentinel in Bavaria, Germany during 2010/2011. Swab specimens were analysed for influenza A(H1N1)pdm09, A(H3) and B by PCR. VE was estimated using the test-negative case-control study design and logistic regression. In total, 1866 patients (790 cases, 1076 controls) were included. The VE of trivalent vaccines administered in season 20

APA, Harvard, Vancouver, ISO, and other styles

10

U., Anuja, Rajasi R. S., Ratheesh K. H., VijayaKumar K., and Amar Fettil. "Seroconversion following H1N1 influenza vaccination among health care personnel in South Kerala, India." International Journal Of Community Medicine And Public Health 4, no. 2 (2017): 428. http://dx.doi.org/10.18203/2394-6040.ijcmph20170267.

Full text

Abstract:

Background: Health care workers were prioritized by World Health Organization (WHO) for H1N1 vaccination during 2009 swine influenza pandemic following which in Kerala, a total of 72,000 people mostly health care personnel were immunized with a single dose of inactivated split influenza monovalent H1N1 vaccine in 2010. The present study was carried out with the objective to find out the proportion of health care workers seroconverted in Kerala following H1N1 vaccination.Methods:A cross-sectional study conducted in three districts of Kerala. Blood samples collected from 193 health staffs were a

APA, Harvard, Vancouver, ISO, and other styles

11

Fiore, Anthony E. "2009 Influenza A(H1N1) Monovalent Vaccines for Children." JAMA 303, no. 1 (2010): 73. http://dx.doi.org/10.1001/jama.2009.1929.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Gorres, J. Patrick, Kelly M. Lager, Wing-Pui Kong, et al. "DNA Vaccination Elicits Protective Immune Responses against Pandemic and Classic Swine Influenza Viruses in Pigs." Clinical and Vaccine Immunology 18, no. 11 (2011): 1987–95. http://dx.doi.org/10.1128/cvi.05171-11.

Full text

Abstract:

ABSTRACTSwine influenza is a highly contagious viral infection in pigs that significantly impacts the pork industry due to weight loss and secondary infections. There is also the potential of a significant threat to public health, as was seen in 2009 when the pandemic H1N1 influenza virus strain emerged from reassortment events among avian, swine, and human influenza viruses within pigs. As classic and pandemic H1N1 strains now circulate in swine, an effective vaccine may be the best strategy to protect the pork industry and public health. Current inactivated-virus vaccines available for swine

APA, Harvard, Vancouver, ISO, and other styles

13

Ellebedy, Ali H., Thomas P. Fabrizio, Ghazi Kayali, et al. "Contemporary Seasonal Influenza A (H1N1) Virus Infection Primes for a More Robust Response To Split Inactivated Pandemic Influenza A (H1N1) Virus Vaccination in Ferrets." Clinical and Vaccine Immunology 17, no. 12 (2010): 1998–2006. http://dx.doi.org/10.1128/cvi.00247-10.

Full text

Abstract:

ABSTRACT Human influenza pandemics occur when influenza viruses to which the population has little or no immunity emerge and acquire the ability to achieve human-to-human transmission. In April 2009, cases of a novel H1N1 influenza virus in children in the southwestern United States were reported. It was retrospectively shown that these cases represented the spread of this virus from an ongoing outbreak in Mexico. The emergence of the pandemic led to a number of national vaccination programs. Surprisingly, early human clinical trial data have shown that a single dose of nonadjuvanted pandemic

APA, Harvard, Vancouver, ISO, and other styles

14

Onlamoon, Nattawat, Petai Unpol, Michittra Boonchan, et al. "Immune Activation and Viral Replication after Vaccination with an Influenza A H1N1 2009 Vaccine in HIV-Infected Children Receiving Antiretroviral Therapy." Disease Markers 35 (2013): 221–27. http://dx.doi.org/10.1155/2013/276547.

Full text

Abstract:

Immunization with a pandemic influenza A H1N1 2009 was recommended for HIV-infected patients. However, there is limited information concerning the impact of immunization with this vaccine on immune activation and HIV viral replication. In this study, 45 HIV-infected children and adolescents receiving antiretroviral therapy were immunized with a 2-dose series of nonadjuvated monovalent influenza A H1N1 2009 vaccine upon enrollment and approximately 1 month later. Immunogenicity was determined by haemagglutination inhibition assay. The level of immune activation was determined by identification

APA, Harvard, Vancouver, ISO, and other styles

15

Jackson, Lisa A., Shital M. Patel, Geeta K. Swamy, et al. "Immunogenicity of an Inactivated Monovalent 2009 H1N1 Influenza Vaccine in Pregnant Women." Journal of Infectious Diseases 204, no. 6 (2011): 854–63. http://dx.doi.org/10.1093/infdis/jir440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Song, Joon Young, Hee Jin Cheong, Jung Yeon Heo, et al. "Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea." Vaccine 29, no. 7 (2011): 1395–98. http://dx.doi.org/10.1016/j.vaccine.2010.12.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

de Lavallade, Hugues, Paula Lorraine Garland, Takuya Sekine, et al. "2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection." Blood 116, no. 21 (2010): 677. http://dx.doi.org/10.1182/blood.v116.21.677.677.

Full text

Abstract:

Abstract Abstract 677 In 2009 the spread of influenza A (H1N1) satisfied the World Health Organization (WHO) criteria for a global pandemic and led to the initiation of a vaccination campaign to ensure protection for the most vulnerable patients. However, the immunogenicity of the 2009 H1N1 vaccine in immunocompromised patients has not been specifically evaluated. Furthermore, the number of doses of vaccine required for effective immunization against H1N1 has not been established. Whereas the European Medicines Agency (EMEA) and the UK Department of Health (DoH) recommended the injection of tw

APA, Harvard, Vancouver, ISO, and other styles

18

Dhedin, Nathalie, Jacques-Olivier Bay, Patricia Ribaud, et al. "Response to Adjuvanted Monovalent Influenza A (H1N1)v Vaccine In Allogeneic Hematopoietic Stem Cell Transplant Recipients." Blood 116, no. 21 (2010): 1269. http://dx.doi.org/10.1182/blood.v116.21.1269.1269.

Full text

Abstract:

Abstract Abstract 1269 Background: Influenza is a potentially serious infection after hematopoietic stem cell transplantation (HSCT). Prolonged immunosuppression leads to impaired immunity to infectious agents that contributes to the poor outcome after HSCT. Vaccination is the main prophylactic approach in individuals at an increased risk for severe influenza disease, but it is less effective in immunocompromised patients. Nevertheless, annual vaccination against influenza is recommended for HSCT recipients, starting at 6 months after transplant. In 2009, due to the emergence of a pandemic inf

APA, Harvard, Vancouver, ISO, and other styles

19

JACKSON, M. L., A. BELLAMY, M. WOLFF, H. HILL, and L. A. JACKSON. "Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults." Epidemiology and Infection 144, no. 4 (2015): 768–71. http://dx.doi.org/10.1017/s0950268815002058.

Full text

Abstract:

SUMMARYNon-steroidal anti-inflammatory drugs (NSAIDs) may inhibit antibody production by peripheral blood mononuclear cells; one consequence of this could be decreased effectiveness of vaccines in NSAID users. Because many older adults use low-dose aspirin for primary or secondary prevention of coronary events, any inhibitory effect of aspirin on vaccine immune response could reduce the benefits of vaccination programmes in older adults. We tested whether immune response to vaccination differed between users vs. non-users of low-dose aspirin, using data from four randomized trials of monovalen

APA, Harvard, Vancouver, ISO, and other styles

20

McVernon, Jodie, and Terry Nolan. "Panvax®: a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009." Expert Review of Vaccines 10, no. 1 (2011): 35–43. http://dx.doi.org/10.1586/erv.10.143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Moro, Pedro L., Oidda I. Museru, Karen Broder, et al. "Safety of Influenza A (H1N1) 2009 Live Attenuated Monovalent Vaccine in Pregnant Women." Obstetrics & Gynecology 122, no. 6 (2013): 1271–78. http://dx.doi.org/10.1097/aog.0000000000000010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Wiwanitkit, Viroj. "Safety of Influenza A (H1N1) 2009 Live Attenuated Monovalent Vaccine in Pregnant Women." Obstetrics & Gynecology 123, no. 3 (2014): 665–66. http://dx.doi.org/10.1097/aog.0000000000000153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Nolan, Terry, Jodie McVernon, Maryanne Skeljo, et al. "Immunogenicity of a Monovalent 2009 Influenza A(H1N1) Vaccine in Infants and Children." JAMA 303, no. 1 (2010): 37. http://dx.doi.org/10.1001/jama.2009.1911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Huijskens, Elisabeth, John Rossen, Paul Mulder, et al. "Immunogenicity, Boostability, and Sustainability of the Immune Response after Vaccination against Influenza A Virus (H1N1) 2009 in a Healthy Population." Clinical and Vaccine Immunology 18, no. 9 (2011): 1401–5. http://dx.doi.org/10.1128/cvi.05046-11.

Full text

Abstract:

ABSTRACTThe emergence of a new influenza A virus (H1N1) variant in 2009 led to a worldwide vaccination program, which was prepared in a relatively short period of time. This study investigated the humoral immunity against this virus before and after vaccination with a 2009 influenza A virus (H1N1) monovalent MF59-adjuvanted vaccine, as well as the persistence of vaccine-induced antibodies. Our prospective longitudinal study included 498 health care workers (mean age, 43 years; median age, 44 years). Most (89%) had never or only occasionally received a seasonal influenza virus vaccine, and 11%

APA, Harvard, Vancouver, ISO, and other styles

25

Nunes, Marta, Anushka Aqil, Saad Omer, and Shabir Madhi. "The Effects of Influenza Vaccination during Pregnancy on Birth Outcomes: A Systematic Review and Meta-Analysis." American Journal of Perinatology 33, no. 11 (2016): 1104–14. http://dx.doi.org/10.1055/s-0036-1586101.

Full text

Abstract:

Objective Numerous observational studies have evaluated the relationship between influenza vaccination during pregnancy and birth outcomes. The number of studies on this subject has increased, especially after the 2009 A/H1N1 pandemic (A/H1N1pdm09). This meta-analysis aims to determine the impact of maternal vaccination with either seasonal trivalent inactivated influenza vaccines (IIV) or A/H1N1pdm09 monovalent vaccines on the rates of preterm (PTB), small for gestational age (SGA), and low birth weight (LBW) births. Methods English language randomized controlled trials and observational stud

APA, Harvard, Vancouver, ISO, and other styles

26

PEBODY, R. G., N. ANDREWS, D. M. FLEMING, et al. "Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom." Epidemiology and Infection 141, no. 3 (2012): 620–30. http://dx.doi.org/10.1017/s0950268812001148.

Full text

Abstract:

SUMMARYAn analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specific adjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (9

APA, Harvard, Vancouver, ISO, and other styles

27

Yang, Penghui, Li Xing, Chong Tang, et al. "Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine." Cellular & Molecular Immunology 7, no. 2 (2010): 116–22. http://dx.doi.org/10.1038/cmi.2009.116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Cheong, Hee Jin, Joon Young Song, Jung Yeon Heo, et al. "Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea." Vaccine 29, no. 3 (2011): 523–27. http://dx.doi.org/10.1016/j.vaccine.2010.10.060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lai, Yi-Chun, Kuen-Cheh Yang, Szu-Min Hsieh, Chien-An Yao, Long-Teng Lee, and Kuo-Chin Huang. "Persistence of Immunogenicity of a Monovalent Influenza Virus A/H1N1 2009 Vaccine in Healthy Volunteers." Clinical and Vaccine Immunology 19, no. 3 (2012): 429–35. http://dx.doi.org/10.1128/cvi.05528-11.

Full text

Abstract:

ABSTRACTAfter WHO declared H1N1 pandemic, global vaccination was carried out immediately after much research. However, the data on long-term immunogenicity were lacking. We aimed to investigate the long-term immunogenicity of different H1N1 vaccine dosage groups 24 weeks after vaccination by a randomized clinical trial. A total of 218 participants were stratified into adult (≤60 years old) and elderly (>60 years old) groups. The adults were randomized in a 1:1:1 ratio. The first group received a single dose of vaccine with 15 μg hemagglutination antigen (HA). The other two groups received t

APA, Harvard, Vancouver, ISO, and other styles

30

Viganò, Alessandra, Vania Giacomet, Elena Pariani, et al. "Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial." Clinical and Vaccine Immunology 18, no. 9 (2011): 1503–9. http://dx.doi.org/10.1128/cvi.05200-11.

Full text

Abstract:

ABSTRACTFew data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines for HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 versus 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV) to HIV-infected children, adolescents, and young adults. A total of 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2

APA, Harvard, Vancouver, ISO, and other styles

31

Jackson, Alan C., Luiz C. Mostaço-Guidolin, Hasantha Sinnock, Songul Bozat-Emre, Michael Routledge, and Salaheddin M. Mahmud. "Pandemic H1N1 Vaccination and Incidence of Acute Disseminated Encephalomyelitis in Manitoba." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43, no. 6 (2016): 819–23. http://dx.doi.org/10.1017/cjn.2016.291.

Full text

Abstract:

AbstractBackground: An increased incidence of hospital admissions coded as acute disseminated encephalomyelitis (ADEM) was noted in Winnipeg, Manitoba, Canada, during the second wave of the influenza pandemic from October 2009 to March 2010. However, it was not clear whether this was due to heightened awareness of potential neurological complications of influenza or influenza vaccination or an actual increase in the number of cases. Methods: We extracted data from the charts of 139 patients hospitalized with an International Classification of Diseases-10 discharge code indicating ADEM (G04.0)

APA, Harvard, Vancouver, ISO, and other styles

32

Sbidian, Emilie, Pirayeh Eftekahri, Manuelle Viguier, et al. "National Survey of Psoriasis Flares after 2009 Monovalent H1N1/Seasonal Vaccines." Dermatology 229, no. 2 (2014): 130–35. http://dx.doi.org/10.1159/000362808.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Probst, Peter, John B. Grigg, Emily A. Hemann, et al. "Small molecule agonists of IRF3 activation function as influenza vaccine adjuvants by modulating the humoral and cellular anti-viral immune response." Journal of Immunology 196, no. 1_Supplement (2016): 76.2. http://dx.doi.org/10.4049/jimmunol.196.supp.76.2.

Full text

Abstract:

Abstract We have identified a panel of small molecule immunomodulators that activate IRF3 and induce innate immune signaling to drive an antigen-specific protective immune response against viral infections. Our lead adjuvant candidate, KIN1148, binds to retinoic acid inducible gene-I (RIG-I) and induces RIG-I signaling to drive IRF3 activation. Studies using the H1N1 influenza virus challenge model demonstrate that immunization with monovalent influenza split vaccine (SV) and KIN1148 is dose sparing and protects mice against a lethal H1N1 A/California/04/2009 challenge. The SV-H1N1/KIN1148 adj

APA, Harvard, Vancouver, ISO, and other styles

34

Xu, Yiqing, Nanda Methuku, Praveena Coimbatore, et al. "Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer." Oncologist 17, no. 1 (2012): 125–34. http://dx.doi.org/10.1634/theoncologist.2011-0220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Yanagisawa, Naoki, Kazuhiro Maeda, Atsushi Ajisawa, et al. "Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects." Vaccine 29, no. 34 (2011): 5694–98. http://dx.doi.org/10.1016/j.vaccine.2011.06.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Yen, Ting-Yu, Shiann-Tarng Jou, Yung-Li Yang, et al. "Immune response to 2009 pandemic H1N1 influenza virus A monovalent vaccine in children with cancer." Pediatric Blood & Cancer 57, no. 7 (2011): 1154–58. http://dx.doi.org/10.1002/pbc.23113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Donohue, Matthew P., Zhijun Cao, Thomas Bowen, Robert Dickinson, Ying Zhang, and Jiang Qian. "The CombE-IDMS Alternate Potency Method for H5N1 and H5N8 Cell-Based Vaccines." Vaccines 11, no. 12 (2023): 1799. http://dx.doi.org/10.3390/vaccines11121799.

Full text

Abstract:

Assaying the potency of inactivated viral influenza vaccines is performed using single radial immunodiffusion, which is the globally accepted release method for potency. Under conditions of a rapidly emerging pandemic, such as the 2009 H1N1 influenza pandemic, a recognized obstacle in the delivery of vaccines to the public is the time needed for the distribution of calibrated SRID reagents (antisera and antigen standards) to vaccine manufacturers. Previously, we first described a novel streamlined MS-based assay, CombE-IDMS, which does not rely on antisera/antibodies or reference antigens, as

APA, Harvard, Vancouver, ISO, and other styles

38

Handabile, Chimuka, Toshiki Sekiya, Naoki Nomura, et al. "Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection." Vaccines 10, no. 5 (2022): 804. http://dx.doi.org/10.3390/vaccines10050804.

Full text

Abstract:

Despite the use of vaccines, seasonal influenza remains a risk to public health. We previously proposed the inactivated whole virus particle vaccine (WPV) as an alternative to the widely used split vaccine (SV) for the control of seasonal and pandemic influenza based on the superior priming potency of WPV to that of SV. In this study, we further examined and compared the immunological potency of monovalent WPV and SV of A/California/7/2009 (X-179A) (H1N1) pdm09 (CA/09) to generate immune responses against heterologous viruses, A/Singapore/GP1908/2015 (IVR-180) (H1N1) pdm09 (SG/15), and A/duck/

APA, Harvard, Vancouver, ISO, and other styles

39

Zhou, Ying, Diane M. W. Ng, Wing-Hong Seto, et al. "Seroprevalence of Pandemic H1N1 Antibody among Health Care Workers in Hong Kong Following Receipt of Monovalent 2009 H1N1 Influenza Vaccine." PLoS ONE 6, no. 11 (2011): e27169. http://dx.doi.org/10.1371/journal.pone.0027169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Nayak, Jennifer L., Theresa F. Fitzgerald, Katherine A. Richards, Hongmei Yang, John J. Treanor, and Andrea J. Sant. "CD4+ T-Cell Expansion Predicts Neutralizing Antibody Responses to Monovalent, Inactivated 2009 Pandemic Influenza A(H1N1) Virus Subtype H1N1 Vaccine." Journal of Infectious Diseases 207, no. 2 (2012): 297–305. http://dx.doi.org/10.1093/infdis/jis684.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Xu, Yiqing, Nanda K. Methuku, Praveena Coimbatore, et al. "Effective Immune Response In Patients Who Have Hematologic Malignancies After Vaccination with Inactivated Influenza A (H1N1) 2009 Monovalent Vaccine." Blood 116, no. 21 (2010): 1743. http://dx.doi.org/10.1182/blood.v116.21.1743.1743.

Full text

Abstract:

Abstract Abstract 1743 Introduction: Effective vaccinations against 2009 H1N1 have been reported in healthy individuals; however, the response of immunocompromised patients, particularly patients who have hematologic malignancies and who also may be taking cytotoxic myelosuppressive and immunosuppressive treatments, is unclear and is generally considered to be decreased. Methods: We conducted a prospective study to test the immunogenicity of H1N1 vaccination in patients with hematologic malignancies. We enrolled 22 patients, all of them received inactivated monovalent H1N1 2009 vaccine made by

APA, Harvard, Vancouver, ISO, and other styles

42

Castilla, Jesús, Julio Morán, Víctor Martínez-Artola, et al. "Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: Cohort and case-control study." Vaccine 29, no. 35 (2011): 5919–24. http://dx.doi.org/10.1016/j.vaccine.2011.06.063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Waibel, Kirk H., and Robert Gomez. "Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines." Journal of Allergy and Clinical Immunology 125, no. 3 (2010): 749–51. http://dx.doi.org/10.1016/j.jaci.2009.12.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Arjona, Miguel Angel Ortiz, Khaled Mahmoud Abd Elaziz, Jose Maria Caballero Lanzas, and Mohamed Farouk Allam. "Coverage and side effects of influenza A(H1N1) 2009 monovalent vaccine among primary health care workers." Vaccine 29, no. 37 (2011): 6366–68. http://dx.doi.org/10.1016/j.vaccine.2011.04.117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Rouleau, Isabelle, Gaston De Serres, Jean Philippe Drolet, et al. "Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine." Vaccine 31, no. 50 (2013): 5989–96. http://dx.doi.org/10.1016/j.vaccine.2013.10.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Tiu, Ceres T., Yu Shia Lin, Murali Pagala, et al. "Antibody Response to Inactivated Influenza A (H1N1) 2009 Monovalent Vaccine in Patients With and Without HIV." JAIDS Journal of Acquired Immune Deficiency Syndromes 58, no. 3 (2011): e99-e102. http://dx.doi.org/10.1097/qai.0b013e318232b50e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Stockman, J. A. "Immunogenicity of a Monovalent 2009 Influenza A(H1N1) Vaccine in Infants and Children: A Randomized Trial." Yearbook of Pediatrics 2011 (January 2011): 274–76. http://dx.doi.org/10.1016/s0084-3954(10)79754-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Matyushenko, Victoria A., Arina D. Kostromitina, Ekaterina A. Stepanova, Larisa G. Rudenko, and Irina N. Isakova-Sivak. "Stability of vaccine strains of seasonal live attenuated influenza vaccines when adapted to MDCK cell culture." Journal of microbiology, epidemiology and immunobiology 102, no. 3 (2025): 296–309. https://doi.org/10.36233/0372-9311-669.

Full text

Abstract:

Introduction. Currently, the vast majority of influenza vaccines in the world are produced using developing chicken embryos as substrate, but there is an urgent necessity for transferring vaccine production to continuous cell lines, which would ensure uninterrupted production during an avian influenza pandemic and also allow the vaccine to be administered to individuals with chicken protein allergies. When vaccine strains of live attenuated influenza vaccine (LAIV) grow in mammalian cells, adaptation mutations can occur that may affect the antigenic and immunogenic properties of the vaccine. T

APA, Harvard, Vancouver, ISO, and other styles

49

Hakim, Hana, Kim J. Allison, Lee-Ann Van De Velde, Yimei Li, Patricia M. Flynn, and Jonathan A. McCullers. "Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults." Vaccine 30, no. 5 (2012): 879–85. http://dx.doi.org/10.1016/j.vaccine.2011.11.105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Njuguna, Henry, Jamal Ahmed, Prisca A. Oria, et al. "Uptake and effectiveness of monovalent influenza A (H1N1) pandemic 2009 vaccine among healthcare personnel in Kenya, 2010." Vaccine 31, no. 41 (2013): 4662–67. http://dx.doi.org/10.1016/j.vaccine.2013.07.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!